COVID-2019. COVID-19, virus identified
Conditions
Interventions
Intervention 1: Intervention group: Nanocurcumin, which is curcumin, is derived from the yellow-cucumber plant, which is embedded in nano-lipid structures for further absorption. The drug is manufactu
Sponsors
Tabriz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Confirmation of positive for coronavirus by RT-pcr Willingness to cooperate In accordance with clinical diagnosis or etiologic criteria for coronavirus pneumonia (COVID-19). Able to sign informed consent
Exclusion criteria
Exclusion criteria: Nutrition and antioxidant supplements and alpha lipoic acid during one month before study Pregnancy and lactation Severe immune suppression (HIV infection, long-term use of immunosuppressive agents) Unwillingness to continue cooperation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Expression of peripheral blood mononuclear cell (PBMC)- Genes Expressed in Nano-Curcumin Patients with Control Group (Before and After Treatment). Timepoint: At baseline and 14 days later. Method of measurement: Real time Polymerase chain reaction.;The secretion rate of peripheral blood mononuclear cell (PBMC)-treated cytokines in nano-curcumin patients and control group (before and after treatment). Timepoint: At baseline and 14 days later. Method of measurement: Elisa kit.;Clinical features. Timepoint: At baseline and 14 days later. Method of measurement: Clinical observations by specialists.;Laboratory observations. Timepoint: At baseline and 14 days later. Method of measurement: Review by a pulmonary specialist. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMajid Ahmadi
Tabriz University of Medical Sciences
Outcome results
None listed